HIV Pharmaceuticals (Direct) Settlement
Sign up below to collect your portion of this $246 million settlement
$246,750,000
February 1, 2018 – September 27, 2022
To Be Determined
Gilead Sciences & Bristol-Myers Squibb
Class Action Refund is a leading third-party claims-filing company that offers full-service claims monitoring and management. We are not class counsel or a claims administrator. Founded in 2003, we have extensive experience managing various class member claims, specifically complex settlement recoveries in claims management, business administration, legal, technology, research, and finance.
Class Action Refund can help your company recover its portion of the Settlement by managing and optimizing all aspects of your claim, including claim filing, communications with the claims administrator, and audit responses. By organizing and handling all the forms and data associated with filing your claim, we will ensure that it meets all requirements and is submitted accurately. By utilizing Class Action Refund’s claims-filing service, your company will incur no upfront costs and recover the maximum amount due back to you.
The settlement alleges that Gilead violated federal antitrust laws by engaging in unlawful conduct to delay competition of generic versions of the HIV medications Atripla and Truvada. The settlement alleges that Gilead entered into a “reverse payment” settlement with Teva Pharmaceuticals, through which it paid Teva to delay entry of its generic versions of Atripla and Truvada. The settlement also alleges that this arrangement resulted in direct purchasers of Atripla, Truvada, and their generic equivalents paying overcharges.
A reverse payment settlement, also known as a “pay-for-delay” settlement, refers to a legal agreement reached between a brand-name drug manufacturer and a generic drug manufacturer. In a reverse payment settlement, the brand-name pharmaceutical company makes financial or other types of valuable concessions to the generic drug manufacturer. In exchange, the generic manufacturer agrees to delay the entry of its generic version of a drug into the market for a specified period, typically until the brand-name drug’s patent exclusivity expires.
Any person or entity in the United States or its territories that purchased Atripla, Truvada, or their generic equivalents directly from a brand or generic manufacturer of those drugs at any time from February 1, 2018, until September 27, 2022.